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ABSTRACT
Due to a homozygous Gly204Arg mutation in the factor X (FX) gene no detectable FX antigen was found in the plasma of a one-year
old patient with severe bleeding diathesis. The amino acid replacement destabilized the disulfide bond that holds the two FX chains
together, decreasing the interaction between the Cys201-Cys206 loop region and the region connecting the EGF2 and serine protease
domains. Both Gly204 FX and Arg204 FX were synthesized in transfected cells, but only the wild type protein became secreted. The
mutant protein was diverted from the normal secretory pathway and retained at the trans Golgi-late endosome level.
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Introduction
Blood coagulation factor X (FX) is synthesized in the liver as a
single chain protein.1,2 During maturation, a tripeptide, Arg140-
Lys141-Arg142, is cut out from the peptide chain in the Golgi.
The resultant 17-kDa light-chain and 45-kDa heavy-chain are
held together by a disulfide-bridge between Cys132 and
Cys302. The light chain contains a Gla domain, two epidermal
growth factor (EGF) domains and an additional connecting
region (CR). The heavy chain consists of the serine protease
(SP) domain and the N-terminal activation peptide (AP) that is
cleaved off upon activation by factors IXa or VIIa. Inherited FX
deficiency is a rare (1:1,000,000) coagulopathy with severe
bleeding symptoms in homozygous patients.1 More than 80
mutations have been described in the F10 gene (www.med.
unc.edu/isth/mutations-databases), the majority of which are mis-
sense mutations. In type I FX deficiency, both functional activ-
ity and antigen level are decreased, while in type II deficiency
a dysfunctional molecule is present. A few reports have sug-
gested that secretion defects, due to missense mutations in
domains of the mature protein, cause type I deficiency.
However, this has been proved by expression studies.3-5 Here
we demonstrated that Gly204Arg substitution resulted in
severe type I FX deficiency by causing structural changes in the




A one-year-old boy with subdural hematoma and bruising
had highly prolonged prothrombin time and activated partial
thromboplastin time. The activity of all clotting factors, except
for FX, was in the reference interval. A highly reduced FX activ-
ity (1%) together with FX antigen concentration below the
limit of detection suggested type I FX deficiency. No bleeding
history in the family was reported. The study protocol was
approved by the Ethics Committee of the University. Informed
consent was given by the patient’s mother. 
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Procedures
With the exception of exon 8, primers described in the
literature were used for amplification of genomic
DNA.3,6,7 The following primers were designed for the
amplification of exon 8: 5’-CGTCTGTCCCAGGGGAC-
3’ (forward), 5’- TGGGATCTCACTTTAATGGAG-3’
(reverse). Forward and reverse direct fluorescent
sequencing of PCR products were performed by ABI
PRISM 310 DNA sequencer (Perkin-Elmer, Foster City,
CA, USA).  The mutant FX expression vector8 was gener-
ated by site-directed mutagenesis of the wild type FX
cDNA inserted in pCMV4 vector using QuickChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA,
USA). Human embryonic kidney (HEK293) cells were
transiently transfected8 with 1 Ìg wild type or mutant
vector using Effectene transfection reagent (Qiagen).
After a 72-hour incubation conditioned media were col-
lected, part of the cells were used for confocal laser scan-
ning microscopy (CLSM), while another part of the cells
was lysed in a buffer containing 50 mM Tris-HCl (pH
7.5), 150 mM NaCl, 1% Nonidet P40, 0.5% sodium
deoxycholate and a protease inhibitor cocktail (Roche).
Aliquots of the media and cell lysates were used for FX
antigen determination by ELISA (Asserachrom X:Ag,
Diagnostica Stago, Asnières, France) and for immunopre-
cipitation by biotinylated goat anti-human FX antibody
(Haematologic Technologies Inc, Vermont, VT) and strep-
tavidine agarose (Sigma-Aldrich). Immunoprecipitates
were analyzed by Western blotting using rabbit anti-
human FX antibody (Dako, Glostrup, Denmark) and
Vectastain Elite ABC kit (Vector Laboratories,
Burlingame, CA, USA). The reaction was visualized by
ECL Plus chemiluminescence reagent (Amersham, Little
Chalfont, UK).
For pulse chase analysis, transfected HEK 293 cells
were preincubated with methionine-, and FCS-free
medium for 30 min. Then they were pulse-labeled for 30
min with 0.5 mCi/mL [35S]methionine (Amersham), and
chased for 30 min, 2 and 6 hr. FX immunoprecipitated
from cell lysates and culture media was analyzed by SDS
PAGE and fluorography. 
Cells fixed in 96% ethanol, 1% acetic acid were incu-
bated with 5% normal human serum in phosphate
buffered saline for 15 min to prevent non-specific IgG
binding. Staining for FX was combined with the detec-
tion of calnexin (an endoplasmic reticulum marker), or
mannosidase II (a cis-Golgi marker), or mannose 6 phos-
phate receptor (a trans-Golgi-late endosome marker).9-11
Cell preparations were examined by CLSM (LSM 410,
Zeiss, Oberkochen, Germany). The relative amount of
FX was determined by measuring integrated fluorescence
intensity on 150-200 cells/slide.12 Molecular modeling
and simulations were performed on reconstituted single-
chain (des1-45)FX.13,14 After minimization and heating up
dynamics, the geometries of Gly204 and Arg204 EGF2-
CR-AP-SP construct were submitted to molecular
dynamics simulation using OPLS/AA force field and peri-
odic boundary conditions with TIP4P water solvent
model with the GROMACS package.15
Results and Discussion
Molecular genetic analysis revealed a homozygous
G>A missense mutation at coding nucleotide position
c.730 resulting in a Gly204Arg replacement in the amino
acid sequence. The mother was heterozygous for the
mutation; the father was unknown and other family
members were not available for testing. The absence of
the mutation in one hundred healthy individuals suggest-
ed its causative nature. We have given a preliminary
presentation of this mutation16 and later it was also
detected in an Iranian patient.5
Using ELISA technique and quantitative fluorescent
image analysis, in HEK cells expressing Arg204 FX the
concentration of FX was found to be 1.5-fold and 2.2-fold
Figure 1. Detection of factor X expressed by HEK293 cells transfect-
ed with wild type and mutant factor X constructs. A. Detection of FX
in the cell lysate (1-3) and culture media (4-6) by Western blotting.
SDS PAGE was performed in non-reducing condition. 1,4: non-trans-
fected cells; 2,5: cells expressing wild type FX; 3,6: cells expressing
Arg204 mutant FX; 7: purified FX standard. FX in the cell lysate had
slightly higher mobility than FX in the culture media or FX prepared
from human plasma, the difference probably reflects different stages
of glycosylation. B. Metabolic labeling of HEK cells expressing wild
type and mutant factor X. Non-transfected (NT) HEK293 cells and
cells transfected with wild type (W) and Arg204 mutant (M) con-
structs were pulse labeled with [35S] methionine, then chased for var-
ious intervals. Cell lysate samples represent immunoprecipitates
from ∼5×105 cells, while culture media samples were immunoprecip-
itated from the supernatant of ∼2.5×105 cells. The immunoprecipi-
tates loaded onto the gels derived from the same amount of proteins
in each sample. HC: FX heavy chain; LC: FX light chain. 
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A non-secretable factor X mutant 
higher respectively than in cells expressing wild type FX.
In agreement with these results, the band representing
Arg204 FX on the Western blot was more intense than
the band corresponding to Gly204 FX (Figure 1A). FX
appeared as a double band which is probably due to the
different extent of glycosylation.2,17 In the media of cells
expressing wild type FX 93.7 mU/mL FX was measured
by ELISA, while FX could not be detected in the media
of cells expressing the mutant protein. Immediately after
pulse labeling of HEK cells, the band of wild type FX was
more intense than the band representing Arg204 mutant
(Figure 1B). During the chase period the amount of radio-
labeled wild type FX rapidly decreased in the cell lysate,
and, in parallel, bands representing FX heavy and light
chains appeared in the culture media. In contrast, the
intensity of the band corresponding to the mutant pro-
tein increased during the first 30 min in the cell lysate
and only then started to decay. No mutant FX appeared
in the culture media. Evidently, newly synthesized wild
type FX became secreted and rapidly disappeared from
the cells, while the mutant proteins, which cannot be
secreted, accumulated in the cytoplasm and were finally
eliminated by intracellular proteases. Double immuno-
fluorescent staining showed that the localization of
Arg204 FX in HEK cells neither corresponded to the
localization of the endoplasmic reticulum (Figures 2Ba-c)
nor to that of the cis-Golgi apparatus (Figures 2Bd-f).
However, the staining for Arg204 FX appeared in co-
localization with the trans-Golgi-late endosome network
(Figures 2Bg-i). No such co-localization was found in the
case of wild type protein (Figures 2Ag-i). The results sug-
gest that the mutant FX is diverted from the normal
secretory pathway toward the late endosomes, and final-
ly becomes degraded in lysosomes.
The site of the mutation is located in a small disul-
phide-bridged loop formed between Cys201 and
Cys206. Cys201, Gly204 and Cys206 residues were
highly conserved during evolution and they are also pres-
ent in factor VII, the closest relative of FX (SwissProt
database). From in silico experiments (Figure 3), it is evi-
dent that the replacement of small apolar glycine at posi-
tion 204 by the bulky positively charged arginine intro-
duces major structural changes into its surroundings. The
region between Cys132 and Arg142, which corresponds
with the C-terminal part of the light chain plus the
tripeptide, has different orientation and lies much farther
from the Cys201-Cys206 disulphide bridged loop than in
wild type FX. The mean Coulomb interaction energy
between the loop and the Cys132-Arg142 peptide seg-
ment was lower in the wild type protein than in the
Arg204 mutant (-188.6 kcal/mol versus -88.5 kcal/mol),
i.e. in the case of the mutant the interaction considerably
weakened. The Cys132 residue is involved in the forma-
tion of the disulfide bond that keeps the EGF2 and SP
domains together, the mutation could prevent the forma-
tion of this disulfide bond or make it unstable and might
in this way also influence the global folding of the pro-
tein. The structural changes could also alter the molecu-
lar recognition and/or transport properties of FX and con-
tribute to the secretion defect of Arg204 mutant.
A
B
Figure 2. Double immunofluorescent staining for FX and intracellular
organelle markers in HEK cells expressing wild type (A) or Arg204
mutant (B) factor X. Goat anti-human factor X antibody
(Haematologic Technologies), followed by biotinylated anti-goat IgG
(Vector) and Texas Red Streptavidin (Vector) were used to detect FX.
Monoclonal primary antibodies against calnexin and mannose 6
phosphate receptor and rabbit antibody against mannosidase II were
from Abcam (Cambridge, UK). The respective secondary antibodies
(Vector) were labeled with fluorescein. Confocal laser scanning micro-
scopic images (magnification 100 × 3,2). a-c: immunostaning for FXα
and the endoplasmic reticulum marker, calnexin; d-f: immunostaning
for FX and mannosidase II, a cis-Golgi marker; g-i: immunostaning for
FX and mannose-6P receptor, a trans-Golgi marker. FX (a,d,g) appears
in red; calnexin (b), mannosidase II (e) and mannose 6P receptor (h)
appear in green; c,f and i are merged images. 
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Figure 3. Averaged three-dimensional structure for wild type (A) and Gly204Arg mutant (B) factor X. The starting structure obtained from the
Research Collaboratory for Structural Bioinformatics, Protein Data Bank (www.rcsb.org) was supplemented according to Venkateswarlu et al.14
The geometries of Gly204 and Arg204 EGF2-CR-AP-SP constructs were submitted to a 7 nanosecond molecular dynamics simulation (6
nanoseconds equilibration and 1 nanosecond sampling). Results were visualized by the Visual Molecular Dinamics software suit.18 Parts of epi-
dermal growth factor 2 (transparent green), activation peptide (steal blue), serine protease (transparent pink) domains and the whole connect-
ing region (gold) are shown on the figure. The Arg140-Lys141-Arg142 tripeptide is depicted in yellow. Selected amino acid residues as well as
the disulfide bonds Cys132-Cys302 and Cys201-Cys206 are shown by ball-and-stick model. The location of Cys201-Cys206 loop is shown in
opaque pink. The distance between the 204 Cα and 137 Cα atoms is shown by a double-headed red arrow.
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